ATE468396T1 - Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems - Google Patents

Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems

Info

Publication number
ATE468396T1
ATE468396T1 AT97905737T AT97905737T ATE468396T1 AT E468396 T1 ATE468396 T1 AT E468396T1 AT 97905737 T AT97905737 T AT 97905737T AT 97905737 T AT97905737 T AT 97905737T AT E468396 T1 ATE468396 T1 AT E468396T1
Authority
AT
Austria
Prior art keywords
nucleic acid
high affinity
complement system
acid ligands
protein
Prior art date
Application number
AT97905737T
Other languages
English (en)
Inventor
Gregory Biesecker
Larry Gold
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE468396T1 publication Critical patent/ATE468396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97905737T 1996-02-01 1997-01-30 Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems ATE468396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59533596A 1996-02-01 1996-02-01
PCT/US1997/001739 WO1997028178A1 (en) 1996-02-01 1997-01-30 High affinity nucleic acid ligands of complement system proteins

Publications (1)

Publication Number Publication Date
ATE468396T1 true ATE468396T1 (de) 2010-06-15

Family

ID=24382833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905737T ATE468396T1 (de) 1996-02-01 1997-01-30 Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems

Country Status (7)

Country Link
EP (1) EP0888374B1 (de)
JP (1) JP2000505646A (de)
AT (1) ATE468396T1 (de)
AU (1) AU2256197A (de)
CA (2) CA2243578C (de)
DE (1) DE69739880D1 (de)
WO (1) WO1997028178A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20120322329A1 (en) * 2010-03-15 2012-12-20 Mitsui Chemicals, Inc Fiber, nonwoven fabric and application thereof
EP2872147B1 (de) 2012-07-13 2022-12-21 Wave Life Sciences Ltd. Verfahren zur herstellung von chiralen oligonukleotiden

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
AU1435492A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
EP0724647A4 (de) * 1993-09-08 2003-09-17 Gilead Sciences Inc Nukleinsäureliganden und verbesserte methoden zu ihrer herstellung
AU2994997A (en) * 1996-05-07 1997-11-26 T Cell Sciences, Inc. Aptamers for complement protein c3b

Also Published As

Publication number Publication date
DE69739880D1 (de) 2010-07-01
CA2243578C (en) 2008-03-25
EP0888374A1 (de) 1999-01-07
JP2000505646A (ja) 2000-05-16
EP0888374A4 (de) 2004-10-27
WO1997028178A1 (en) 1997-08-07
AU2256197A (en) 1997-08-22
CA2243578A1 (en) 1997-08-07
CA2630098A1 (en) 1997-08-07
EP0888374B1 (de) 2010-05-19

Similar Documents

Publication Publication Date Title
ATE470712T1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
ATE184052T1 (de) Gdf-1 und uog1 proteine
DE69835143D1 (de) Selektion von proteinen mittels rns-protein fusionen
DE69636656D1 (de) Oligonukleotidliganden mit hoher affinität für pdgf
ATE83801T1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
DK1015586T3 (da) TIE-receptortyrosinkinaseligandhomologer
CY1105161T1 (el) Ομολογα προσδεματος τιε
ATE282087T1 (de) Modifiziertes enzym mit lipolytischer aktivität
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE378417T1 (de) Polymerase-verbessernder faktor (pef)-enthaltende extrakte, pef proteinkomplexe, isoliertes pef protein und verfahren zur reinigung und identifizierung
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
DK1082423T3 (da) Cyclin E2-gener og -proteiner
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
ATE223491T1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
ATE468396T1 (de) Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems
ATE427959T1 (de) Gereinigtes sr-p70 protein
DE69734586D1 (de) Retinoid-metabolisierendes protein
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
DE69927668D1 (de) Massenfingerabdrucken und seiner verwendung zur identifizierung von protein-affinitätsliganden
EP0970192A4 (de) Nukleinsäure, die für das algu protein von m. tuberculosis kodiert.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties